Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03897998 · ClinicalTrials.gov registry record · Phase 2

Neural Correlates of Hypoalgesia Driven by Observation

A Phase 2 study of Pain and Virtual Reality, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Phase 2
Development phase
182
Enrollment target
1
Study location

NCT03897998: Recruiting Phase 2 study of Pain and Virtual Reality, sponsored by University of Maryland, Baltimore.

NCT03897998 is a Phase 2 study of Pain and Virtual Reality that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 182 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03897998, a Phase 2 study of Pain and Virtual Reality, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Phase 2
Development phase
182 participants
Enrollment target
1
Study location

Study Summary

Placebo effects held an ambivalent place in health care for at least two centuries. On the one hand, placebos are traditionally used as controls in clinical trials to correct for biases and the placebo response is viewed as an effect to be factored out in order to isolate and accurately measure the effects of the treatment. On the other hand, there is scientific evidence that placebo effects represent fascinating psychoneurobiological events involving the contribution of distinct central nervous as well as peripheral physiological mechanisms that influence pain perception and clinical pain symptoms and substantially modulate the response to pain therapeutics. Therefore, placebo effects have shifted from being a challenge for clinical trials to a resource to trigger the reduction of pain based on endogenous mechanisms that can be activated in the brain to promote hypolagesia, self-healing, and well-being. This is relevant in acute pain settings given that chronic opioid users die within approximately 2.5 years of being prescribed their first opioid medication to treat acute pain. The overall hypothesis is that observational learning influences neural pain modulation and cognition systems, including processes associated with mentalizing (the ability to cognitively understand mental states of others), empathy (the ability to share an emotional experience), and expectancy (the anticipation of a benefit). The objective is to determine the brain mechanisms of observationally-induced analgesia using brain mapping approaches that target changes in blood oxygenation and oscillatory activity in the brain, thus enabling investigators to draw inferences about the localization and extent of neurobiological activation underlying hypoalgesia driven by observation. Therefore, the investigators designed innovative experiments using pharmacological fMRI, EEG, and combined EEG-fMRI measurements.

Primary Outcome

Blood oxygenation level dependent (BOLD) responses will allow the identification of relative activation/deactivation in the brain as result of events (e.g. painful stimulations) that will be given during the experiment and the treatment administration.

Interventions

  • OTHER Saline
  • DRUG Naloxone

Study Locations (1)

Maryland

  • University of Maryland - Baltimore

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2021-11-01
Est. Completion 2025-12-31
Phase Phase 2
University of Maryland, Baltimore

560 total trials

What NCT03897998 shows while recruiting

NCT03897998 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (40% lower).

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT03897998 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03897998 about?

NCT03897998 is a clinical study titled "Neural Correlates of Hypoalgesia Driven by Observation". Placebo effects held an ambivalent place in health care for at least two centuries. On the one hand, placebos are traditionally used as controls in clinical trials to correct for biases and the placebo response is viewed as an effect to be factored out in order to isolate and accurately measure the ...

What is the current status of trial NCT03897998?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2021-11-01. Estimated completion is 2025-12-31.

What conditions does trial NCT03897998 study?

This clinical trial studies the following conditions: Pain, Virtual Reality, Placebo.

What interventions are being tested in trial NCT03897998?

The interventions under investigation include: Saline (OTHER), Naloxone (DRUG).

Who is sponsoring clinical trial NCT03897998?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03897998 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03897998's enrollment target sits among peer trials

182 99th of 374 higher than 276 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • NCT04323735 · 182 participants · Phase 2

    Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

  • NCT05606731 · 182 participants · NA

    Family Intervention to Prevent Childhood Obesity

  • NCT06084936 · 182 participants · Phase 3

    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03897998, the US trial registry maintained by the National Library of Medicine. NCT03897998 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.